Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.008
Neutral
RSI(14)
47.900
Neutral
STOCH(KDJ)(9,3,3)
58.197
Neutral
ATR(14)
0.092
Low Volatility
CCI(14)
104.345
Buy
Williams %R
45.000
Neutral
TRIX(12,20)
-0.354
Sell
StochRSI(14)
53.375
Sell
Search
Autolus Therapeutics PLC
AUTLAdd to Watchlist
1.490USD
-0.040-2.61%
Close 07-31 16:00（ET）Quotes delayed by 15 min
396.57MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey ChartIntraday
1m
30m
1h
D
W
M
D
Today
-2.61%
5 Days
+2.76%
1 Month
-5.70%
6 Months
+7.97%
Year to Date
-25.13%
1 Year
-36.60%
Key Figures
1.530Open
1.550High
815.26KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.31%Turnover Ratio
1.530Prev. Close
1.470Low
925.67KTurnover
LossP/E Static
2.23P/B
0.00%Div Yield TTM
-45.38%ROA
2.70052wk High
0.96Volume Ratio
-220.66MNet Profit
266.14MShares
-1.0857EPS TTM
1.98Beta
-120.42%ROE
1.17552wk Low
5.23%Amplitude
6.29%Gross Margin
396.57MMarket Cap
-1.37Reward/Risk
4.48%Risk Rate
TradingKey Stock Score of Autolus Therapeutics PLC
Currency: USD Updated: 2026-07-31Key Insights
Autolus Therapeutics PLC's fundamentals are relatively stable, and its growth potential is high.Its valuation is considered fairly valued, ranking 53 out of 385 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 8.27.In the medium term, the stock price is expected to remain stable.Despite a weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Autolus Therapeutics PLC's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
Autolus Therapeutics PLC Highlights
StrengthsRisks
Autolus Therapeutics plc is a United Kingdom-based early commercial-stage biopharmaceutical company developing programmed T cell therapies for the treatment of cancer and autoimmune diseases. The Company has an approved commercial product, AUCATZYL, for the treatment of adult patients with r/r B-ALL. Using a suite of proprietary and modular T cell programming technologies, it is also developing five programs in seven hematological and solid tumor indications and one autoimmune indication. It is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and attack and eliminate these cells. Its product pipeline includes obe-cel (ALLCAR19), obe-cel (CAROUSEL), AUTO1/22 (CARPALL), AUTO4 (LibrA T1), AUTO6 (MAGNETO), AUTO5, AUTO8 (MCARTY) and AUTO9. AUTO4 and AUTO5 are two programmed T cell therapies for the treatment of peripheral T-cell lymphoma targeting TRBC 1 and TRBC 2.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 4339.81% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 75.39M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 75.39M.
Overvalued
The company’s latest PE is -1.37, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 209.95M shares, decreasing 19.28% quarter-over-quarter.
Held by Steven Cohen
Star Investor Steven Cohen holds 350.74K shares of this stock.
Analyst Rating
Based on
10
analysts
Buy
Current Rating
8.267
Target Price
+454.81%
Upside Space
Autolus Therapeutics PLC News
More news coming soon, stay tuned...
Earnings Forecast
Analyst Rating
Based on
10
analysts
Buy
Current Rating
8.267
Target Price
+454.81%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
160
Total
6
Median
9
Average
Company name
Ratings
Analysts
Autolus Therapeutics PLC
AUTL
10
Biogen Inc
BIIB
38
Amgen Inc
AMGN
38
Eli Lilly and Co
LLY
35
Pfizer Inc
PFE
32
AbbVie Inc
ABBV
32
1
2
3
...
32
Indicators
Moving Average
Indicators
Value
Direction
MA5
1.478
Buy
MA10
1.466
Buy
MA20
1.512
Sell
MA50
1.570
Sell
MA100
1.532
Sell
MA200
1.534
Sell
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Autolus Therapeutics PLC Info
Autolus Therapeutics plc is a United Kingdom-based early commercial-stage biopharmaceutical company developing programmed T cell therapies for the treatment of cancer and autoimmune diseases. The Company has an approved commercial product, AUCATZYL, for the treatment of adult patients with r/r B-ALL. Using a suite of proprietary and modular T cell programming technologies, it is also developing five programs in seven hematological and solid tumor indications and one autoimmune indication. It is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and attack and eliminate these cells. Its product pipeline includes obe-cel (ALLCAR19), obe-cel (CAROUSEL), AUTO1/22 (CARPALL), AUTO4 (LibrA T1), AUTO6 (MAGNETO), AUTO5, AUTO8 (MCARTY) and AUTO9. AUTO4 and AUTO5 are two programmed T cell therapies for the treatment of peripheral T-cell lymphoma targeting TRBC 1 and TRBC 2.
Ticker SymbolAUTL
CompanyAutolus Therapeutics PLC
CEOItin (Christian Martin)
Websitehttps://www.autolus.com/
Shareholders
Related Instruments
-0.53%
+0.27%
-2.51%
+0.32%
-1.45%
-0.92%
-0.64%
-0.82%
-8.79%
+0.52%
+0.68%
-0.95%
-0.71%
+0.44%
-1.08%
+3.29%
0.00%
-0.90%
+1.30%
-2.15%Popular Instruments
52762.200
+384.200 (+0.73%)
28497.200
+336.300 (+1.19%)
7531.100
+56.000 (+0.75%)
14597.000
-152.000 (-1.03%)
63765.000
+913.000 (+1.45%)
6400.000
+34.600 (+0.54%)
77.982
-7.952 (-9.25%)
308.910
-24.520 (-7.35%)
200.750
+5.710 (+2.93%)
4064.750
+23.320 (+0.58%)
FAQs
What is the current price of Autolus Therapeutics PLC (AUTL)?
The current price of Autolus Therapeutics PLC (AUTL) is 1.49.
What is the symbol of Autolus Therapeutics PLC?
The ticker symbol of Autolus Therapeutics PLC is AUTL.
What is the 52-week high of Autolus Therapeutics PLC?
The 52-week high of Autolus Therapeutics PLC is 2.70.
What is the 52-week low of Autolus Therapeutics PLC?
The 52-week low of Autolus Therapeutics PLC is 1.18.
What is the market capitalization of Autolus Therapeutics PLC?
The market capitalization of Autolus Therapeutics PLC is 396.57M.
Is Autolus Therapeutics PLC (AUTL) currently rated as Buy, Hold, or Sell?
According to analysts, Autolus Therapeutics PLC (AUTL) has an overall rating of Buy, with a price target of 8.27.
What is the Earnings Per Share (EPS TTM) of Autolus Therapeutics PLC (AUTL)?
The Earnings Per Share (EPS TTM) of Autolus Therapeutics PLC (AUTL) is -1.08.